Scientific Program

Thursday, December 7, 2017 +
Time Topic Session
1:00pm-5:30pm
Registration Sign-In
6:45pm-7:00pm
Opening Remarks
Alphonse E. Sirica, Ph.D., M.S. (VCU) 
SESSION 1: Hepatobiliary Cancer Risk Conditions and Prevention Strategies

Chairs: Anna Mae Diehl, M.D., Hashem B. El-Serag, M.D., M.P.H.
Key Topic Areas: Focus on known risk conditions for primary liver cancers, with added emphasis on prevention strategies.

Time Presentation Title and Speaker* Ϯ
7:00pm-7:30pm
The changing etiology of liver cancer, challenges for the next 20 years

John D. Groopman, Ph.D. (Johns Hopkins)

7:30pm-8:00pm 
Prevention of hepatitis C related hepatocellular carcinoma

Hashem B. El-Serag, M.D., M.P.H. (Baylor College of Medicine)

8:00pm-8:30pm 
Liver repair and risk for liver cancer

Anna Mae Diehl, M.D. (Duke)

8:30pm-8:45pm 
Refreshment Break 
8:45pm-9:15pm
Steatohepatitis accelerates HCC development in mice

Gyongyi Szabo, M.D., Ph.D. (UMass)

9:15pm-9:45pm
Novel molecular approaches to HCC risk assessment and prevention

Laura Beretta, Ph.D. (MD Anderson)

Friday, December 8, 2017 +
6:30am-7:45am
Conference Continental Breakfast
 
SESSION 2: Molecular Signaling Pathways, Pathogenesis, and Hepatic Oncogenesis

Chairs: Lopa Mishra, M.D., George K. Michalopoulos, M.D., Ph.D.
Key Topic areas: Focus on dysregulated signaling, cellular and molecular pathogenesis, and metabolic pathways relevant to hepatobiliary cancer development and progression.

Time Presentation Title and Speaker* Ϯ
8:00am-8:30am
Cellular dynamics and signaling pathways linking liver regeneration to hepatocarcinogenesis

George K. Michalopoulos, M.D., Ph.D. (Univ. Pittsburgh)

8:30am-9:00am
Obesity driven HCC: the critical role of the p62-NRF2 axis

Michael Karin, Ph.D. (UC San Diego)

9:00am-9:30am
Modeling human HCC in mice: biological and therapeutic implications

Paul Monga, M.D. (Univ. Pittsburgh)

9:30am-9:45am
Refreshment Break
9:45am-10:15am
Evidence for cancer stem cells and altered TGF-β stem niche in hepatocarcinogenesis

Lopa Mishra, M.D. (George Washington Univ.)

10:15am-10:45am
Mechanisms of invasiveness in cholangiocarcinoma: a potential therapeutic target

Mario Strazzabosco, M.D., Ph.D. (Yale Univ.)

10:45am-11:15am
Membrane cytoskeletal dynamics in hepatobiliary tumor metastasis

Mark A. McNiven, Ph.D. (Mayo)

11:15am-11:45am
IDH mutant cholangiocarcinoma

Nabeel M. Bardeesy, Ph.D. (Mass General, Harvard)

12:00pm-1:15pm
Conference Lunch
 
SESSION 3: Microenvironment and Hepatobiliary Cancer Progression 

Chairs: Gregory J. Gores, M.D., Scott L. Friedman, M.D.
Key Topic Areas: Focus on current mechanism-based studies aimed at elucidating the origins, cellular and molecular interactions, tumor promoting effects, prognostic implications, and therapeutic potential of targeting cancer-associated fibroblasts in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Time Presentation Title and Speaker* Ϯ
1:30pm-2:00pm
Fibrotic stromal links to liver carcinogenesis

Scott Friedman, M.D. (Mount Sinai)

2:00pm-2:30pm
Hepatic stellate cells and hepatocellular carcinoma

Robert F. Schwabe, M.D. (Columbia Univ.)

2:30pm-3:00pm
Modeling the desmoplastic stromal of intrahepatic cholangiocarcinoma for therapeutic targeting

Alphonse E. Sirica, Ph.D., M.S. (VCU)

3:00pm-3:15pm
Refreshment Break
3:15pm-3:45pm
Targeting cancer-associated fibroblasts for the treatment of cholangiocarcinoma

Gregory J. Gores, M.D. (Mayo)

3:45pm-4:15pm
Transcriptomic dissection of liver cancer risks in cirrhosis

Yujin Hoshida, M.D., Ph.D. (Mount Sinai)

4:15pm-4:30pm
Abstract-driven short talk
4:30pm-4:45pm
Abstract-driven short talk
5:30pm-7:30pm
Early Investigator Meet and Greet Reception

(includes heavy Hors doeuvres and beverages)

7:45pm-9:45pm
Early Investigator Poster Session

This session is abstract driven and will be used to highlight research by early career investigators that fits into the major themes covered by the conference. Submitted abstracts by young investigators, to include Ph.D. Graduate Students, Postdoctoral Fellows, M.D. Residents and Fellows, and Assistant Professors within 1 year of their initial appointment, will be assessed by the Conference Chair and Co-Chairs, as well as appointed Session Topic Chairs, for their originality, innovation, quality of content, relevance, and scientific impact. Based on these criteria, up to 40 abstracts will be chosen for poster presentation, with those judged to be in the top 4-to-6 also eligible for oral presentation in a designated platform session. Posters will be available for viewing throughout the days of December 8 and 9, with attendance by the presenters required during the full two hour time period of the Early Investigator Poster Session. Travel Awards for top 4-to-6 selected abstracts.

Saturday, December 9, 2017 +
6:30am-7:45am
Conference Continental Breakfast
 
SESSION 4: MicroRNAs in Hepatobiliary Cancer Growth, Progression, and Therapy

Chairs: Gianfranco D. Alpini, Ph.D., Florin M. Selaru, M.D., M.B.A.
Key Topic areas: Focus on the involvement of deregulated microRNAs on oncogenic pathways in primary liver cancers and their potential as therapeutic targets for hepatocellular and cholangiocellular carcinomas.

Time Presentation Title and Speaker* Ϯ
8:00am-8:30am
Role of the miR-34a-dependent clock gene, Per1, in the regulation of cholangiocarcinoma growth

Gianfranco Alpini, Ph.D. (Baylor Scott & White, Texas A&M, Central Texas Veterans Health Care System)

8:30am-9:00am
Argonaute CLIP defines a deregulated miR-122 bound transcriptome that predicts patient survival in human liver cancer

Kalpana Ghoshal, Ph.D.  (Ohio State Univ.)

9:00am-9:30am
Epigenetic regulation of miRNAs in liver cancers

Tong Wu, M.D., Ph.D.  (Tulane Univ.)

9:30am-9:45am
Refreshment Break
9:45am-10:15am
Extracellular vesicles deliver microRNA species to liver cancers in animal models

Florin M. Selaru, M.D., M.B.A. (Johns Hopkins Univ.)

10:15am-10:30am
Abstract-driven short talk
10:30am-10:45am
Abstract-driven short talk
10:45am-11:00am
The Cholangiocarcinoma Foundation Presentation

Stacie Lindsey, B.A., President and Founder

11:00am-11:50am
Keynote Lecture: Liver cancer prevention and treatment: A US perspective

Douglas R. Lowy, M.D., Acting Director of the National Cancer Institute, NIH

12:00pm-1:15pm
Conference Lunch
 
SESSION 5: Genomics and Personalized Medicine for Primary Liver Cancers 

Chairs: Josep M. Llovet, M.D., Snorri S.Thorgeirsson, M.D., Ph.D..
Key Topic Areas: Focus will be on genomic analyses and informatics to identify signature gene expression profiles in the pathogenesis, molecular classifications, and personalized therapeutics of primary hepatobiliary cancers.

Time Presentation Title and Speaker* Ϯ
1:30pm-2:00pm
Molecular drivers and targeted therapies in HCC

Josep M. Llovet, M.D. (Mount Sinai & Univ. Barcelona)

2:00pm-2:30pm
Using preclinical models to identify predictors of response to targeted therapeutics

Richard Finn, M.D. (UCLA)

2:30pm-3:00pm
Modeling and predicting metastasis in hepatocellular carcinoma

Dean W. Felsher, M.D., Ph.D. (Stanford Univ.)

3:00pm-3:15pm
Refreshment Break
3:15pm-3:45pm
Stemness and reprogramming in liver cancer

Snorri S. Thorgeirsson, M.D., Ph.D. (NCI-NIH)

3:45pm-4:15pm
Cancer genomic heterogeneity and integrated genomics to define primary liver cancers

Xin Wei Wang, Ph.D. (NCI-NIH)

4:15pm-4:30pm
Abstract-driven short talk
4:30pm-4:45pm
Abstract-driven short talk
4:45pm-5:00pm
Blue Faery-The Adrienne Wilson Liver Cancer Association Presentation

Andrea J. Wilson, MPW, ACC, President and Founder

 
SESSION 6: Molecular Therapeutic Targeting of Hepatocellular and Cholangiocellular Carcinomas

Chairs: Lewis R. Roberts, M.B., Ch.B., Ph.D., Andrew X. Zhu, M.D., Ph.D..
Key Topic Areas: Focus will be on novel rational approaches for targeted therapies of hepatobiliary cancers, to include advances in immunotherapeutics and combinational treatment modalities.

 

Time Presentation Title and Speaker* Ϯ
6:30pm-7:00pm
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets

Andrew X. Zhu, M.D., Ph.D. (Mass General, Harvard)

7:00pm-7:30pm
Immune based therapies: From mouse models to clinical trials

Tim F. Greten, M.D. (NCI-NIH)

7:30pm-8:00pm
Glypican-3 as a liver cancer target for antibody- based therapies

Mitchell Ho, Ph.D. (NCI-NIH)

8:00pm-8:15pm
Refreshment Break
8:15pm-8:45pm
Targeting the fibroblast growth factor receptor pathway in hepatobiliary cancers

Lewis R. Roberts, M.B., Ch.B., Ph.D. (Mayo)

8:45pm-9:15pm
Therapeutics for the pediatric cancer fibrolamellar hepatocellular carcinoma

Sanford M. Simon, Ph.D. (Rockefeller Univ.)

9:15-9:30pm
Closing Remarks

Alphonse. E. Sirica, Ph.D., M.S. (VCU)

Sunday, December 10, 2017 +
6:30am-9:00am
Conference Continental Breakfast
9:00am
Conference Ends

*Oral presentations by Invited Speakers will be 25 minutes, with an additional 5 minutes for questions. Abstract-driven short talks will be 10 minutes, with 5 additional minutes for questions.

Ϯ Titles of individual oral presentations provided by the Invited Speakers are presumptive and may change to reflect new key basic and translational research findings and biomedical advances.           

 

Hepatobiliary Cancers Evaluation Form